Regulatory support for FDA IND application: qgrft for the prevention of sars-COV-2 infection. This is a covid-19 requirement.
Ended Purchase Order Awarded Last action
- Contract number
- 75N95021P00464
- Awardee
-
Novotech Drug Development Consulting LLC UEI NL1CNS4ZP7X4
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $45,608
Award facts
- Opportunity
-
- Regulatory Support for FDA IND Application: QGRFT for the Prevention of SARS-CoV-2 Infection. This is a COVID-19 requirement Solicitation · 75N95021Q00319 · Posted Aug 17, 2021
- Contract value 100% obligated
- $45,607.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Boulder, CO 80301, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$2,393 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $48,000 |
About this award
This is a $45,607.50 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Novotech Drug Development Consulting LLC (doing business as CBR International, LLC) for regulatory support services related to an Investigational New Drug (IND) application for a COVID-19 prevention therapy called QGRFT.
The order stems from a previous NCATS requirement for pre-IND activities on QGRFT, and this contract will enable the continued regulatory support needed to advance QGRFT through clinical trials. There was no set-aside designation for this award. Novotech, a small business contract research organization, has extensive experience providing regulatory expertise and operational support for the development of treatments and vaccines, including COVID-19 therapeutics.
Quick answers
Who was awarded contract 75N95021P00464?
75N95021P00464 was awarded to Novotech Drug Development Consulting LLC by National Institute on Drug Abuse (National Institutes of Health) on August 20, 2021.
How much is contract 75N95021P00464 worth?
The government has obligated $45,608 on 75N95021P00464.
Which agency awarded contract 75N95021P00464?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95021P00464, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95021P00464 competed?
The extent of competition for 75N95021P00464 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award